Trial Profile
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48 Weeks in Participants Who Have Completed 96 Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Elvucitabine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Achillion Pharmaceuticals; Alexion Pharmaceuticals
- 21 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jun 2008 New trial record.